accepting new patients

Dr. El-Jawahri is an oncologist specializing in the care of patients with hematologic malignancies and those undergoing hematopoietic stem cell transplantation. Clinically, she takes care of patients with acute leukemia, myelodysplastic syndrome, chronic leukemias, lymphomas, and myelomas. Her research interests include investigating patient-reported outcomes, enhancing patient-centered decision-making interventions, and designing supportive care interventions to improve the care of patients with hematologic malignancies with a special emphasis on patients undergoing hematopoietic stem cell

As Director of the Stanford MDS Center, Dr Greenberg has an active clinical practice focusing on myelodysplastic syndromes (MDS) and clonal myeloid disorders. His clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the impact of molecular mutations for a risk-based prognostic system, the IPSS

Carlo Dufour works in G.Gaslini Research Children’s Hospital, Genova, Italy, the largest, multi specialist pediatric hospital of the country, where he chairs the Hemo-Onco- HSCT Department and the Hematology Unit where have seat the national Registry of Neutropenia, the national Registry of Alps and related disorders and the national Data Base of Fanconi Anemia. He founded the Marrow Failure Syndromes Study Group within the Italian Pediatric Hemato- Oncology Association (AIEOP). He is author or co-author of over 200 international publications and of various hematology textbook and text book

I am a pediatric hematologic oncologist and Chief of the Pediatric Stem Cell Transplantation and Cellular Therapies Service. I specialize in bone marrow and cord blood transplantation to treat blood diseases in children and young adults. I have particular expertise caring for people with rare diseases, such as lysosomal storage disorders like Hurler’s disease and leukodystrophies like metachromatic leukodystrophy, adrenoleukodystrophy, and Krabbe disease. I am also part of a dedicated team of experts working to develop new treatments for our young patients. At MSK Kids, our goal is to better

I am a hematologist specializing in the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and clonal cytopenias of unknown significance. I received my Master of Science in pathobiology and molecular medicine from the University of Cincinnati, and completed a fellowship in hematology/oncology at the University of Alabama. As a member of the Leukemia Research Program at the OSUCCC – James, my clinical and translational research focus is on novel therapeutics in myeloid diseases, with a special focus in disease progression from

My research focuses on identifying the genetic causes of human diseases as a means to both better diagnosis and treat patients and understand basic biologic principles. We are interested in studying autoimmune and auto-inflammatory diseases to elucidate the mechanism underlying these diseases and improve patient care. We use a combination of genetic, and biochemical approaches in patient derived and animal models to better understand these diseases. Our aim is to directly connect human diseases with basic innate immune biology using genetics.

Dr. Balasubramanian completed his medical training at Madras Medical College in India. His interest in treating malignant hematology patients started in his advanced training in Singapore in the Department of Hematology and Bone Marrow Transplant. He was intrigued by the advancement of cancer genetics and its application in the development of novel therapeutics. He strongly believes in the concept of being a physician-scientist. He completed a year of clinical research fellowship in Neuro-Oncology at Cleveland Clinic, where he investigated the role of EGFR mutations and ALK rearrangement in

Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials. Furthermore, she leads the Chronic Graft-versus-Host Disease/Long-Term Follow-Up Program for patients who have received hematopoietic cell transplantation or other immune

Firas El Chaer, MD, is an assistant professor of medicine who specializes in hematology and oncology. His clinical areas of interest are acute leukemia, chronic leukemia, myelodysplastic syndrome, myeloproliferative disorders, aplastic anemia, clonal hematopoiesis and blood disorders. His research focuses on improving outcomes for acute leukemia in adults by focusing on targeted therapies and overcoming resistance mechanisms. Dr. El Chaer attended medical school at the University of Balamand in Beirut, Lebanon, and completed his internal medicine residency at the Icahn School of Medicine at